Introduction {#Sec1}
============

Social cognition has been defined as the way we perceive, interpret, and understand social information \[[@CR1]\] or as "the processes that allow a person to understand, act on, and benefit from the interpersonal world" \[[@CR2]\]. A further overall definition was given by Adolphs \[[@CR3]\] who described social cognition as "the ability to construct representations of the relation between oneself and others and to use those representations flexibly to guide social behaviour."

Aspects of social cognition include emotion perception, social cue interpretation, attribution style, and theory of mind. Affect perception is the ability to infer emotional information, in other words what a person is feeling, presented either in visual or auditory form. Social cue perception refers to a person's ability to ascertain social cues from behaviour provided in a social context, and refers to a person's comprehension of social rules \[[@CR4]\]. Attribution style, known as a personalizing bias, refers to an individual's own perception and interpretation of facts and events \[[@CR5]\]. The attribution of mental states, such as desires, intentions, and beliefs, to other people has been referred to as "theory of mind" (ToM) or "mentalising" \[[@CR6], [@CR7]\]. ToM involves both the ability to understand that others have mental states different from one's own, and the capability to make correct inferences about the content of those mental states \[[@CR5]\].

The neurophysiological and neurochemical underpinnings of social cognition in schizophrenia are a scientific domain that requires further exploration. Several neurotransmitters seem to play a considerable role in social cognitive processes, and their circuitries are deemed to be altered in schizophrenia. The hypothalamic peptides arginine vasopressin (AVP) and oxytocin (OXT) have been described as social hormones that may mediate social behaviour \[[@CR8]\] including social motivation, approach behaviour \[[@CR9]\], and ToM \[[@CR10], [@CR11]\]. Recently, abnormal oxytocinergic and dopaminergic signalling in the amygdalae has been proposed to explain dysfunction in the social cognitive domain in schizophrenia \[[@CR12]\].

Serotonin is another neurotransmitter linked to social behaviour, including roles in cognition, mood, and aggression, alongside motivation, energy levels, and sleep \[[@CR13], [@CR14]\]. There is increasing interest in the correlation between negative symptoms of schizophrenia and abnormal neurotransmission at serotonin 5-HT~2~ receptors \[[@CR15]\].

Dopamine appears as a key neurotransmitter in the aetiopathogenesis of schizophrenia described as crucially involved in the attribution process as well as emotional perception, giving not only meaning but also salience to the objects in our environment \[[@CR16], [@CR17]\]. Deregulation of the dopaminergic system leads to the production of dopamine regardless of incoming stimuli, which results in giving meaning to their meta-representations, thereby creating a misguided inner reality of actually meaningless objects. This maladaptive attribution system created during psychosis is very often implicated permanently in the patient's experience, regardless of pharmacological blocking of excess dopamine \[[@CR16]\].

A growing body of literature has shown consistently that schizophrenia patients compared with healthy controls present with social cognitive impairments that are relatively stable and persistent, suggesting that it is a trait-dependent rather than state-dependant aspect of the disorder \[[@CR18]--[@CR20]\]. These deficits have been widely described as modifying patients' behaviour when interacting with other people (ToM deficits) \[[@CR7], [@CR20]--[@CR22]\] and in recognizing emotions \[[@CR23]--[@CR25]\] and other social information cues \[[@CR18], [@CR26]\]. Therefore, social cognitive deficits are believed to be important predictors of functional outcome in schizophrenia \[[@CR5], [@CR27]\]. Such deficits represent an obvious substrate for treatment in schizophrenia.

Pharmacological treatment research on social cognition in schizophrenia has been relatively limited: recent data on the effects of second- and first-generation antipsychotics (SGA/FGA) on various domains of social cognition remain inconclusive.

This paper aims (1) to appraise current evidence on the impact of antipsychotics upon social cognitive functioning in schizophrenia, to find out if antipsychotics do really improve social cognitive functions; and if yes, (2) to explore differential medication effects on social cognition, if any.

A comprehensive search of the PsycINFO and MEDLINE/PUBMED databases for articles in English published till 31 December 2012 was conducted. Within the domain of social cognition, the following search terms were used: emotion/affect perception, emotion/affect recognition, attribution/attributional style, theory of mind/mentalising, social cognition, social competence, and social cue perception. Within the domain of psychopharmacology outcome, the following terms were used: conventional antipsychotics, atypical antipsychotics, atypicals, and clinical trials.

Search terms for schizophrenia included the following: psychosis, schizophrenia, and schizoaffective disorder.

Search Strategy {#Sec2}
---------------

The following search keywords were used:schizophrenia AND social cognition AND antipsychotics; 224 articles, 15 utilisedschizophrenia AND emotion perception AND antipsychotics; 63 papers, 6 utilisedschizophrenia AND facial affect AND antipsychotics; 29 papers, 4 utilisedschizophrenia AND theory of mind AND antipsychotics; 14 papers, 3 utilisedschizophrenia AND attribution AND antipsychotics; 20 articles, 0 utilisedschizophrenia AND attributional style AND antipsychotics; 3 articles, 1 utilisedschizophrenia AND social competence AND antipsychotics; 33 articles, 2 utilisedschizophrenia AND social cue perception AND antipsychotics; 2 papers, 1 utilised

Inclusion Criteria {#Sec7}
------------------

The papers were utilised in the current review if they were written in English and had reported experimental studies of aspects of social cognition in schizophrenia treated with antipsychotic medication. Although 32 papers were identified there was much overlap between the results of individual searches: 15 papers in total were accrued from all eight searches and are reviewed here (see Table [1](#Tab1){ref-type="table"}).Table 1Summary of the 15 papers reviewedReferencesStudy designSubject groups with numbersAntipsychotics used (CPZE daily ± SD)Study durationEvaluated social cognitive domainSocial cognitive testsMain resultsCriticismGaebel and Wölwer \[[@CR23]\]RCTS = 23 first-onsetP = 376 mg4 weeksFAREkman and FriesenComparable improvement in FAR in both patient groupsSmall sample sizeH = 445 mgP = 13H = 10HC = 15Lewis and Garver \[[@CR34]\]NCTS = 18 chronicH = 250--1,000 mg2 weeksFAREkman and FriesenNo effect of haloperidol on FARSmall sample sizeH = 18Non-randomisedHC = 10Kee et al. \[[@CR32]\]DBCTS = 18 chronicR = 300 mg8 weeksEmotion perception (FAR, emotion prosody)FEITR \> HSmall sample sizeR = 9H = 750 mgVEITNo improvement of emotion perception in H groupH = 9VAPTWilliams et al. \[[@CR36]\]NCCS = 28 chronicR = 828 ± 493 mgAssessed onceFARColour photographsHC \> R \> HSmall sample sizeR = 15H = 688 ± 601 mgPatients on risperidone performed worse than HC; however, better than H-treated groupNon-randomised\
Use of limited social cognitive measuresH = 13HC = 28Littrell et al. \[[@CR44]\]NCTS = 52 chronicFGAs = 540 ± 215 mg12 monthEmotional perception, perception of social cueIPTImprovement in social cognitive domains in O-treated patients solelySmall sample sizeFGAs = 30\
O = 22Mean O dose = 15.3 mg/dayAssessed at baseline, 12 weeks, and end point (52 weeks)Non-randomisedNo psychopathology ratingHerbener et al. \[[@CR31]\]NCTS = 13 first-onsetR = 169 ± 100 mg31.3 ± 8.3 daysFARPEATNo effect of medications on FARSmall sample sizeR = 9H = 225 ± 35 mgEMODIFFNon-randomisedH = 2Z = 233 mgZ = 1A = 400 mgA = 1HC = 13Harvey et al. \[[@CR29]\]DBCTS = 289 chronicR = 100--400 mg8 weeksEmotion perception, social competencePEATBoth medications improved social competence but not emotion perceptionLack of non-medication control groupR = 154Q = 267--1,067 mgQ = 135Savina and Beninger \[[@CR45]\]Cross-sectionalS = 84 chronicNot providedAssessed onceToMFirst-order belief and second-order belief tasks and faux pas testsFGA and R groups performed worse than other groups on ToM tasks. O and C groups were comparable to HCs on ToM tasksSmall sample size\
Non-randomisedFGAs = 23C = 18O = 20R = 3HC = 24Sergi et al. \[[@CR42]\]DBCTS = 73 chronic\
R = 32\
O = 28\
H = 13R = 48.2 ± 7 mg\
O = 49.2 ± 6 mg\
H = 50.0 ± 5 mg8 weeksEmotion perceptionFEIT\
VEIT\
HPNS\
IPTNo effect of medication on emotion perceptionLack of non-medication control group\
Modest group size\
Random assignment pathsMizrahi et al. \[[@CR21]\]Cross-sectional componentPsychotic disorder = 71\
SGA 88.6 %\
FGA 11.4 %R = 3--4 mg6 weeks (measurements every 2 weeks)ToMHinting taskImprovement on both PANSS and ToM on antipsychoticsNo placebo control groupLongitudinal componentS = 17 first-onset (60 % neuroleptic naive; 40 % drug free)O = 2.5--20 mgL = 35 mgC = 225--300 mgMachado de Sousa and Hallak \[[@CR43]\]Cross-sectionalS = 15\
C = 15 (resistant to treatment) chronic\
HC = 15C = 470 ± 173 mgAssessed onceFARERT (based on pictures of facial affect (Ekman and Friesen))Patients took more time to perform ERT\
Time-related deficits for recognition of fear and disgust in patients were foundSmall sample size\
Non-randomisedFakra et al. \[[@CR46]\]RCTS = 25 chronicR = 298 ± 116 mg1 monthFARFeinberg testR \> H on FARSmall sample size\
Lack of non-medication control groupR = 11H = 398 ± 155 mgH = 14Penn et al. \[[@CR33]\]DBCTS = 873 chronicIdentical-appearing capsules contained O = 7.5 mg; Q = 200 mg; R = 1.5 mg; Pph = 8 mg and Z = 40 mg\
The medication dose ranging from one to four capsules daily, based upon the study doctor's judgement18 monthsEmotion perceptionFEDTLimited medication effect on emotion perception was foundLack of non-medication control groupO = 213Q = 54R = 183\
Combination = 72lAll others = 130Roberts et al. \[[@CR38]\]DBCTS = 223 chronic\
O = 117\
Q = 106O = 312 mg/day\
Q = 607 mg/day6 monthsPerception of social cuesSocial cue recognition testImprovement in both medication groups on 3 out of 4 social cognitive subscalesLack of non-medication control groupKucharska-Pietura et al. \[[@CR35]\]Cross-sectionalS = 84 chronic\
FGA = 28 (Pph = 14; H = 14)\
SGA = 56FGA = 422 ± 219\
SGA:\
 O = 341 ± 118\
 C = 519 ± 276Assessed onceEmotion perception; ToM/empathyFERT\
VERT\
Reading the Mind in the Eyes TestThere were no statistically significant differences on social cognitive performance between FGA and SGA treatment groupsSmall sample size\
Non-randomizedDesigns: *DBCT* double-blind clinical trial, *HC* healthy controls, *NCC* non-randomized case control study, *NCT* non-randomized clinical trial, *RCT* randomized clinical trialMedications: *A* aripiprazole, *C* clozapine, *CPZE* chlorpromazine equivalent, *FGAs* first generation antipsychotics, *H* haloperidol, *L* loxapine, *O* olanzapine, *P* perazine, *Pph* perphenazine, *Q* quetiapine, *R* risperidone, *SGAs* second generation antipsychotics, *Z* ziprasidoneSubject groups: *HC* Healthy Controls, *S* schizophrenia groupSocial cognitive measures: *EMODIFF* Penn Emotion Differentiation Test, *ERT* Emotion Recognition Test, *FEIT* Facial Emotion Identification Test, *FEDT* The Face Emotion Discrimination Task, *HPNS* Half-Profile of Nonverbal Sensitivity, *FERT* Facial Emotion Recognition Test, *IPT* Interpersonal Perception Task, *PEAT* Penn Emotional Acuity Test, Reading the Mind in the Eyes Test, *VAPT* Videotape Affect Perception Test, *VEIT* Voice Emotion Identification Test, *VERT* Voice Emotion Recognition TestSocial cognitive domains: *FAR* Facial Affect Recognition, *ToM* Theory of MindPsychiatric scale: *PANSS* Positive and Negative Syndrome Scale

The Place of Social Cognitive Deficit in Multifactorial Models of Schizophrenia: Symptom, or Neurocognitive Compromise? {#Sec3}
=======================================================================================================================

The analysis of emotional behaviour in schizophrenia is fundamental to the notion of dementia praecox introduced by Kraepelin, and a question fielded by Bleuler on the basis of 'Affektivität': "What happened to feelings in dementia praecox?" This has constituted and still constitutes a scientific challenge \[[@CR28]\]. While symptom-based approaches have understandably dominated most aspects of pharmacological intervention in schizophrenia research, a limited number of studies have investigated the effect of symptoms on social cognition \[[@CR29]--[@CR33]\].

To the best of the authors' knowledge, the majority of studies fail to demonstrate a clear relationship between overall symptom severity scores and performance on social cognitive measures \[[@CR29], [@CR34]--[@CR36]\].

However, there are suggestions that negative and disorganized symptoms may be related to social cognitive functioning \[[@CR21], [@CR23], [@CR31], [@CR37], [@CR38]\].

Relationships among social cognitive constructs and negative symptoms are, however, not clear. Although some overlap exists between negative symptoms and social cognition in schizophrenia, according to participants at a National Institute of Mental Health (NIMH) conference where this issue was addressed \[[@CR39]\] it is unwise to combine the constructs at this point in time. The consensus was that it is more informative to study negative symptoms and social cognition separately and to analyse relationships between them, until we know more about areas of convergence and divergence. Regarding positive symptoms \[[@CR32]\], there has been some linkage between attributional style and paranoid delusions \[[@CR40]\]. There is virtually no literature that has developed the relationship between disorganisation symptoms and social cognition.

Penn et al. \[[@CR1]\] argued that multifactorial models of schizophrenia, including only non-social cognitive processes i.e. 'neurocognition', did not adequately explain the social functioning impairment in schizophrenia. Subsequently, social cognition was seen as a key domain for consideration during the first meeting of the NIMH-sponsored Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative \[[@CR27]\] and it was ultimately included as one of the seven domains represented in the MATRICS Consensus Cognitive Battery for clinical trials in schizophrenia \[[@CR39]\].

Therefore, current accepted wisdom is that social cognitive deficit is a variety of neurocognitive compromise; it does not represent a symptom or group of symptoms by itself. The development of objective tests to quantify degrees of social cognitive impairment argues further for the validity of this construct.

Does Antipsychotic Treatment Improve Social Cognition? {#Sec4}
======================================================

Lewis and Garver \[[@CR34]\] assessed facial affect recognition in 18 patients on haloperidol (5--20 mg/day) compared with 10 healthy controls in the course of their 2-week non-randomised clinical trial. An impairment in facial affect recognition was found in the schizophrenia group. This deficit was not related to psychopathology symptom scores.

Bellack et al. \[[@CR41]\] assessed the effects of clozapine and risperidone on social skills at baseline, week 17, and week 29 in patients with schizophrenia using the Maryland Assessment of Social Competence. No significant medication effect on social competence was found despite clinical improvement on both medications. Similarly, Herbener et al. \[[@CR31]\] described no beneficial effect of antipsychotics after 1 month (nine patients on risperidone) regarding facial affect recognition in 13 patients with first-episode psychosis.

It is worth noting that these studies were not adequately powered to draw definite conclusions. However, two influential randomised studies failed again to support the hypothesis that antipsychotics improve social cognition \[[@CR29], [@CR42]\]. Harvey et al. \[[@CR29]\] found that patients with schizophrenia treated with either risperidone (*n* = 154; 2--8 mg/day) or quetiapine (*n* = 135; 200--800 mg/day) for an 8-week period of double-blind treatment did not improve their facial affect recognition, using the Penn Emotional Acuity Test. Similarly, Sergi et al. \[[@CR42]\] found no evidence of treatment-related differences in social cognition in 73 patients with a diagnosis of schizophrenia in an 8-week double-blind study of risperidone, olanzapine, and haloperidol. Interestingly, when the potential influence of changes in neurocognition was statistically controlled for, there was no within-group change in social cognition. This suggests that social cognition and neurocognition are not the same thing, in other words, they vary independently of each other.

Alternatively, Gaebel and Wölwer \[[@CR23]\] and Roberts et al. \[[@CR38]\] demonstrated, respectively, significant improvement in facial affect recognition in patients on FGAs (haloperidol or perazine) and on the Social Cue Recognition Test in patients treated with olanzapine (*n* = 117) or quetiapine (*n* = 106) \[Table [1](#Tab1){ref-type="table"}\]. Similarly Mizrahi et al. \[[@CR21]\] studied 17 drug-free patients who then received antipsychotic treatment for 6 weeks: the effect on psychotic symptoms and ToM, using a hinting task, was measured every 2 weeks. The hinting task score was associated with negative and general symptom scores. Both the Positive and Negative Syndrome Scale (PANSS) positive scores and ToM improved after medication was started, particularly during the first 2 weeks of antipsychotic treatment.

Surprisingly, Machado de Sousa and Hallak \[[@CR43]\] reported no differences in recognition accuracy or emotional intensity scores within the Facial Emotion Recognition Task between patients on clozapine compared with healthy controls. Since clozapine is a superior antipsychotic drug, this suggests that clozapine treatment may have corrected any deficit. The analysis of individual emotions, however, demonstrated a specific time-related deficit affecting the recognition of fear and disgust. Moreover, Harvey et al. \[[@CR29]\] reported a similar apparent differential effect in patients treated for 8 weeks with quetiapine or risperidone: emotion perception remained unchanged, whereas social competence improved. This correlated with concurrent improvement in other aspects of neuropsychological performance, such as executive function and memory.

Is There Any Differential Effect on Social Cognition Between Antipsychotic Agents? {#Sec5}
----------------------------------------------------------------------------------

A number of influential studies have confirmed that SGAs outperformed FGAs in a range of clinical efficacy parameters, including the domain of social cognition \[[@CR32], [@CR36], [@CR44]--[@CR46]\]. It has been argued that SGAs' strong affinity for 5-HT~2~ receptors \[[@CR14]\] via the disinhibitory effect of serotonin antagonism on dopamine release in the prefrontal area may eventually improve emotion perception and social functioning \[[@CR14]\]. However, both FGAs and SGAs also affect dopamine regulation in the mesocorticolimbic system, which suggests the potential for regulation of the amygdalae as an emotional manager \[[@CR17]\].

Furthermore, clozapine and olanzapine increased dopamine outflow in the medial prefrontal cortex (mPFC), but not in the striatum or nucleus accumbens, whereas haloperidol had no effect in the mPFC but increased dopamine outflow in the striatum \[[@CR47]\].

As a rule of thumb, frontal dopamine deficiency, perhaps as a response to striatal overactivity, has been considered germane to the induction of negative symptoms, associated with cognitive deficit and impaired social cognition. Therefore, trials have investigated the differential effects of FGAs and SGAs upon social cognition.

Kee et al. \[[@CR32]\] evaluated the ability to recognise "emotional" faces in 20 treatment-resistant patients at baseline and after 8 weeks of treatment with risperidone or haloperidol, in a double-blind trial. The results of this study confirmed the positive influence of treatment with risperidone on the performance of facial affect tasks. Williams et al. \[[@CR36]\] later reported similarly, that schizophrenic patients on haloperidol underperformed those on risperidone and healthy controls in recognising facial emotional expressions. Haloperidol-treated patients showed reduced fixation (attention) to salient features for neutral and happy expressions whereas risperidone-treated subjects and healthy controls achieved comparable results, displaying significantly better fixation to salient features for these expressions. This was followed by Littrell et al. \[[@CR44]\] who in an open study found that 22 schizophrenia patients treated with olanzapine for 12 months performed better on a social perception measure, the Interpersonal Perception Task, than 30 patients on FGAs.

Fakra et al. \[[@CR46]\] reported that 25 acute schizophrenia patients randomised to risperidone performed a facial affect discrimination task significantly better than those treated with haloperidol after 4 weeks. It was concluded that risperidone may specifically act on the processing of emotion-laden information: findings could not be explained on the grounds of facial recognition alone. However, Savina and Beninger \[[@CR45]\] demonstrated that ToM performance in schizophrenia patients was related to maintenance, rather than acute treatment effects: they suggested that olanzapine and clozapine, but not risperidone or FGAs, may improve or protect ToM ability in this scenario.

It is worth mentioning that none of the studies above, apart from that of Harvey et al. \[[@CR29]\], was both randomised and adequately powered. The lack of standardised social cognitive measures coupled with psychopathology rating scales detracts from their value. Common sense dictates that the active, distressing symptoms of acutely ill patients and the far from optimal state of arousal that these induce must seriously impair performance of any cognitive task that requires optimal attention and concentration. 'Control' tasks, to uphold the specificity of any improvement in social cognition, are conspicuous by their absence.

Consistent with the conclusion that these positive findings may be more apparent than real is a substantial body of literature reflecting far fewer differences between atypical and conventional antipsychotic drugs than initially suggested \[[@CR48]\].

Of enormous influence is the CATIE trial (Clinical Antipsychotic Trials for Intervention Effectiveness trial), which failed to demonstrate differential antipsychotic effects on social cognition. To wit, Penn et al. \[[@CR33]\] assessed emotion perception in 873 CATIE patients randomised to quetiapine, olanzapine, risperidone, ziprasidone (all SGAs), or perphenazine (FGA). Patients completed the Face Emotion Discrimination Task \[[@CR49]\] immediately prior to randomisation and after 2 months of treatment. At baseline, 60 % of participants were on a SGA, 15 % on a FGA, and 25 % of subjects were antipsychotic free. Non-statistically significant improvement in emotion perception at 2 months was observed: the treatment groups did not differ from one another.

Finally, Kucharska-Pietura et al. \[[@CR35]\] assessed deficits in social cognitive functioning in a naturalistic pragmatic sample of partially remitted stable schizophrenia inpatients, 28 being treated with a FGA (perphenazine or haloperidol), 56 being treated with a SGA (olanzapine or clozapine), and 50 healthy controls. In line with previous findings, there were no differences between the patient groups in emotional perception and ToM/empathy. This is particularly striking given the supposedly superior effects of clozapine previously reported. There were small but significant advantages for SGAs in non-social low-level visual processing: this was thought to result from SGAs' weaker antagonism of dopamine receptors in the retina \[[@CR35]\].

Conclusions {#Sec6}
===========

First, overall, antipsychotic drugs of either class demonstrate little reliable effect upon social cognition \[[@CR38], [@CR50]\]. There is a modicum of support for the use of oxytocin as an adjunct to antipsychotic drugs \[[@CR11]\] but whether this latest finding is a valid effect remains a matter of conjecture. By contrast, recent randomized intervention studies of specialised psychosocial treatment programmes for social cognition report very promising results in the improvement of emotional perception and social skills in schizophrenia \[[@CR50]--[@CR52]\].

Secondly, the literature suffers from inconsistencies in study design, particularly a prevalence of non-randomised approaches based upon cross-sectional assessments, which do not reflect the later NIMH recommendations. Nor are medication doses standardised. Most sample sizes are quite small, and there is inadequate control of pertinent clinical variables. This overlaps with three obstacles to research progress identified by the NIMH group: (1) psychometrics and measurement, (2) maturity of the field, and (3) a lack of interdisciplinary bridges between clinical and basic researchers \[[@CR39]\].

Finally, large-scale longitudinal investigations are needed to explore the unclear relationships between social cognition, symptoms, and functional outcome. If social cognition proves to represent a neurocognitive construct, we suspect related to premorbid personality, then it is not logical to expect current antipsychotic treatments designed to attenuate active symptoms to have any significant effect other than through symptom control, thus abolishing the 'noise' of symptoms in the patient's attempts at social cognitive function. Other treatments, quite possibly training patients in the areas in which they are impaired, may hold more promise.
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